Advanced

Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer

Shaffer, David R; Leversha, Margaret A; Danila, Daniel C; Lin, Oscar; Gonzalez-Espinoza, Rita; Gu, Bin; Anand, Aseem; Smith, Katherine; Maslak, Peter and Doyle, Gerald V, et al. (2007) In Clinical Cancer Research 13(7). p.2023-2029
Abstract
PURPOSE: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent basis in real time with minimal patient discomfort. We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer. EXPERIMENTAL DESIGN: Blood was collected from 63 patients with metastatic prostate cancer. CTCs were isolated by the Cell Search system, which uses antibodies to epithelial cell adhesion marker and immunomagnetic capture. CTCs were defined as nucleated cells positive for cytokeratins and negative for CD45.... (More)
PURPOSE: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent basis in real time with minimal patient discomfort. We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer. EXPERIMENTAL DESIGN: Blood was collected from 63 patients with metastatic prostate cancer. CTCs were isolated by the Cell Search system, which uses antibodies to epithelial cell adhesion marker and immunomagnetic capture. CTCs were defined as nucleated cells positive for cytokeratins and negative for CD45. Captured cells were analyzed by immunofluorescence, Papanicolau staining, and fluorescence in situ hybridization. RESULTS: Most patients (65%) had 5 or more CTCs per 7.5 mL blood sample. Cell counts were consistent between laboratories (c = 0.99) and did not change significantly over 72 or 96 h of storage before processing (c = 0.99). Their identity as prostate cancer cells was confirmed by conventional cytologic analysis. Molecular profiling, including analysis of epidermal growth factor receptor (EGFR) expression, chromosome ploidy, and androgen receptor (AR) gene amplification, was possible for all prostate cancer patients with >or=5 CTCs. CONCLUSIONS: The analysis of cancer-related alterations at the DNA and protein level from CTCs is feasible in a hospital-based clinical laboratory. The alterations observed in EGFR and AR suggest that the methodology may have a role in clinical decision making. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Cancer Research
volume
13
issue
7
pages
2023 - 2029
publisher
American Association for Cancer Research
external identifiers
  • pmid:17404082
  • scopus:34247502671
ISSN
1078-0432
DOI
10.1158/1078-0432.CCR-06-2701
language
English
LU publication?
yes
id
d6e6c7d8-91bf-4b05-b1d3-9256e30ffe1e (old id 1141145)
date added to LUP
2008-08-13 13:09:23
date last changed
2017-11-19 04:16:29
@article{d6e6c7d8-91bf-4b05-b1d3-9256e30ffe1e,
  abstract     = {PURPOSE: To better direct targeted therapies to the patients with tumors that express the target, there is an urgent need for blood-based assays that provide expression information on a consistent basis in real time with minimal patient discomfort. We aimed to use immunomagnetic-capture technology to isolate and analyze circulating tumor cells (CTC) from small volumes of peripheral blood of patients with advanced prostate cancer. EXPERIMENTAL DESIGN: Blood was collected from 63 patients with metastatic prostate cancer. CTCs were isolated by the Cell Search system, which uses antibodies to epithelial cell adhesion marker and immunomagnetic capture. CTCs were defined as nucleated cells positive for cytokeratins and negative for CD45. Captured cells were analyzed by immunofluorescence, Papanicolau staining, and fluorescence in situ hybridization. RESULTS: Most patients (65%) had 5 or more CTCs per 7.5 mL blood sample. Cell counts were consistent between laboratories (c = 0.99) and did not change significantly over 72 or 96 h of storage before processing (c = 0.99). Their identity as prostate cancer cells was confirmed by conventional cytologic analysis. Molecular profiling, including analysis of epidermal growth factor receptor (EGFR) expression, chromosome ploidy, and androgen receptor (AR) gene amplification, was possible for all prostate cancer patients with >or=5 CTCs. CONCLUSIONS: The analysis of cancer-related alterations at the DNA and protein level from CTCs is feasible in a hospital-based clinical laboratory. The alterations observed in EGFR and AR suggest that the methodology may have a role in clinical decision making.},
  author       = {Shaffer, David R and Leversha, Margaret A and Danila, Daniel C and Lin, Oscar and Gonzalez-Espinoza, Rita and Gu, Bin and Anand, Aseem and Smith, Katherine and Maslak, Peter and Doyle, Gerald V and Terstappen, Leon W M M and Lilja, Hans and Heller, Glenn and Fleisher, Martin and Scher, Howard I},
  issn         = {1078-0432},
  language     = {eng},
  number       = {7},
  pages        = {2023--2029},
  publisher    = {American Association for Cancer Research},
  series       = {Clinical Cancer Research},
  title        = {Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer},
  url          = {http://dx.doi.org/10.1158/1078-0432.CCR-06-2701},
  volume       = {13},
  year         = {2007},
}